News | September 22, 2010

FDA-Cleared OCT Intravascular Imaging System on Display at TCT

September 22, 2010 - A new intravascular imaging system will be highlighted at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The C7-XR optical coherence tomography (OCT) platform, made by St. Jude Medical, offers physicians a new tool for intravascular lesion assessment.

The system uses near-infrared light to create high-resolution images, allowing physicians to visualize and measure important vessel characteristics that are otherwise invisible or difficult to assess. While fractional flow reserve (FFR) accurately identifies which lesions to stent, OCT-guided treatment can be especially important for assessing stent placement because it shows precisely how the stent is positioned against the artery wall.

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.

Physicians can learn more about OCT-guided therapy by participating in virtual reality simulations. The simulator enables physicians to manipulate the C7-XR Dragonfly catheter, performing OCT-guided procedures in human-size models and selecting from a variety of case scenarios. The sessions will take place on Sept. 23 and Sept. 24 from 9 a.m. to 5 p.m. and on Sept. 25 from 9 a.m. to 2 p.m. at the St. Jude Medical booth.

St. Jude Medical will also sponsor a scientific symposium entitled, "OCT & FFR, Current Applications, Future Potential." The symposium will take place on Thursday, Sept. 23 from 7 p.m. to 9:30 p.m. in the Renaissance Ballroom, located in the Renaissance Washington, D.C. Downtown Hotel.

For more information: www.sjm.com

Related Content

BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis
News | FFR Technologies| December 28, 2017
HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five...
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
GE Healthcare and Medis Collaborate to Expand Availability of Quantitative Flow Ratio Software
News | FFR Technologies| November 10, 2017
GE Healthcare and Dutch-based cardiovascular imaging software provider Medis announced at the 2017 Transcatheter...
FAVOR II Studies Examine Diagnostic Accuracy of Quantitative Flow Ratio, FFR-Angio.
News | FFR Technologies| November 08, 2017
Investigators in the FAVOR II China and FAVOR II Europe-Japan studies recently presented their results at the 2017...
FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone. TCT 2017

FAME2 cost effectiveness of FFR guided PCI vs. medical therapy alone.

News | FFR Technologies| November 06, 2017
November 6, 2017 — Three-year data from the FAME 2 study show patients with coronary artery disease who underwent a p
Acist Medical Systems Announces Approval and Launch of Next-Generation FFR System
Technology | FFR Technologies| November 03, 2017
Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-...
Philips is partnering with HeartFlow to co-develop new FFR-CT and FFR-angiography imaging technologies.
News | FFR Technologies| August 28, 2017
August 28, 2017 — Philips Healthcare and HeartFlow Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Technologies| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Technologies| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance of coronary lesions to determine if they should be revas
Head-to-Head Study Validates Consistent Performance of Microcatheter FFR
News | FFR Technologies| May 31, 2017
Acist Medical Systems Inc. announced results from the ACIST-FFR Study demonstrating the consistent and correlative...
Overlay Init